Dr. Thomas Hammond
Office room number 5006
Tom graduated in 2006 with a BSc in Pharmacology from the University of Newcastle upon Tyne. Following a spell in industry working at both AstraZeneca and Ferring, Tom returned to academia to undertake both his MRes and PhD. Under the guidance of Dr Dominic Williams, Professor Kevin Park and Dr Gerry Kenna at the MRC Centre for Drug Safety at the University of Liverpool and in close collaboration with AstraZeneca, Tom spent the majority of his MRes investigating the role of Kupffer cells in drug induced liver injury. Upon progression to his PhD, Tom’s research focus developed into investigating the interactions of acyl glucuronide metabolites of carboxylic acid drugs with protein. This work culminated in the first mass-spectrometric identification of acyl glucuronide metabolites covalently bound to human serum albumin isolated from patients receiving diclofenac therapy. This finding reinforces anxiety over acyl glucuronidation as a metabolic pathway of toxicological consequence. Tom’s other research interests throughout his PhD were pharmacokinetics and the utility of continuous intravenous drug infusion models in pre-clinical toxicology. Tom joins the research group to work within the bioanalytical team to quantify steroids in biological matrices, and to investigate signaling pathways of orphan enzymes thought to be involved in steroid metabolism.
Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP and Park BK (2010) Acyl glucuronides: the good, the bad and the ugly. Biopharmaceutics & Drug Disposition 31:367-395
|Hammond, Thomas G.; Moes, Suzette; Youhanna, Sonia; Jennings, Paul; Devuyst, Olivier; Odermatt, Alex; Jenö, Paul: Development and characterization of a pseudo multiple reaction monitoring method for the quantification of human uromodulin in urine, in: Bioanalysis 8, 2016, H. 12, S. 1279-96. edoc (Open Access)|
|Seibert, Julia K.; Quagliata, Luca; Quintavalle, Cristina; Hammond, Thomas G.; Terracciano, Luigi; Odermatt, Alex: A role for the dehydrogenase DHRS7 (SDR34C1) in prostate cancer, in: Cancer medicine 4, 2015, H. 11, S. 1717-1729. edoc|